Program leverages personalized care delivery to help members with

hemophilia live healthy, vibrant lives.

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan

Health, Inc. (NASDAQ: MGLN) today announced that Magellan Rx

Management, the pharmacy benefit management division of the company, has

released results from the first six months of its hemophilia management

program launched in collaboration with Health New England, a non-profit

health plan serving the commercial, Medicaid and Medicare markets.

Hemophilia is a rare genetic bleeding disorder, for which treatment is

expensive and difficult to manage. The average annual cost per member

with severe hemophilia can exceed $250,000, and may be upward of $1

million for members who have developed inhibitors. Personalized care

programs for patients with hemophilia aim to reduce unnecessary costs

while improving the overall quality of care.

“As April 17 is World Hemophilia Day, we’re excited to bring hemophilia

care into the spotlight and highlight the early results achieved with

Health New England through our hemophilia management program,” said

Haita Makanji, vice president, clinical specialty solutions at Magellan

Rx Management. “Through personalized interventions, we’re able to better

determine the individual member needs and coordinate across key

stakeholders to deliver a truly personalized care program that ensures

members with hemophilia receive best-in-class care and achieve optimal

outcomes.”

Since launching the hemophilia management program in August 2017,

Magellan Rx Management and Health New England have standardized care

across various stakeholders without compromising patient outcomes,

resulting in:



  • Optimized doses through assay management or pharmacokinetic (PK)
    testing in 50 percent of members


  • Reduced average assay dispensed in prophylaxis patients from 5 percent
    to 1 percent, reducing the potential for waste


  • No breakthrough bleeding reported from members who had a dose reduction

“In the past eight months of collaboration with Magellan, we’ve achieved

our goals of ensuring high quality of care for members with hemophilia

while minimizing potential waste created through excess dispensing and

inappropriate dosing,” said Andrew J. Colby, R.Ph, MBA, Health New

England's pharmacy director. “By announcing our hemophilia management

program results on World Hemophilia Day, we hope to raise the profile of

this condition and look to continue to make strides in standardizing

best treatment practices to benefit members across the country.”

The hemophilia management program aims to enhance overall quality and

personalization of hemophilia care by coordinating with prescribers,

members and pharmacies while reducing unnecessary costs. Key elements

include:



  • Helping payers analyze information related to member bleed history and
    hemophilia treatment patterns.


  • Standardizing dispensing and optimal dose protocols to promote best
    practices and improve transparency in hemophilia care.


  • Updating policies to encourage individualized treatment regimens based
    on member-specific metabolic factors.

About Health New England: Based in Springfield, Mass., Health New

England is a non-profit health plan serving members in Massachusetts and

Connecticut. A wholly-owned subsidiary of Baystate Health, Health New

England offers a range of health care plans in the commercial, Medicaid

and Medicare markets. For more information, visit healthnewengland.org.

About Magellan Rx Management: Magellan Rx Management is a

full-service PBM that expands beyond traditional core services to help

its customers and members solve complex pharmacy challenges by

connecting them to the people, technology and information they need to

make smarter healthcare decisions. Magellan Rx Management is leading the

next evolution of PBMs by using a value-driven approach that moves past

the traditional volume-focused thinking to deliver true value-driven

solutions, including targeted clinical programs, powerful member and

provider engagement strategies, advanced analytics and expert specialty

pharmacy management capabilities.

About Magellan Health: Magellan

Health, Inc. is a leader in managing the fastest growing, most

complex areas of health, including special populations, complete

pharmacy benefits and other specialty areas of healthcare. Magellan

supports innovative ways of accessing better health through technology,

while remaining focused on the critical personal relationships that are

necessary to achieve a healthy, vibrant life. Magellan's customers

include health plans and other managed care organizations, employers,

labor unions, various military and governmental agencies and third-party

administrators. For more information, visit MagellanHealth.com.

(MGLN-GEN)

Contacts

Magellan Health, Inc.

Media Contact:

Lilly Ackley,

860-507-1923

or

Investor

Contact:

Joe Bogdan, 860-507-1910